share_log

424B3: Prospectus

424B3: Prospectus

424B3:募資說明書
美股SEC公告 ·  2024/11/08 16:26

Moomoo AI 已提取核心訊息

Aclarion, Inc., a healthcare technology company, has filed a prospectus with the SEC detailing the offer and resale of up to 27,515,153 shares of common stock. This includes up to 21,830,104 shares issuable upon conversion of Series C Convertible Preferred Stock and up to 5,685,049 shares issuable upon exercise of warrants, both resulting from a private investment in public equity (PIPE) financing under a Securities Purchase Agreement dated September 30, 2024. Aclarion is not selling any securities under this prospectus and will not receive proceeds from the sale of shares by the Selling Stockholders. However, the company may receive approximately $1.2 million from the cash exercise of the Common Warrants. The shares are to be sold by Selling Stockholders from time to time, at market prices...Show More
Aclarion, Inc., a healthcare technology company, has filed a prospectus with the SEC detailing the offer and resale of up to 27,515,153 shares of common stock. This includes up to 21,830,104 shares issuable upon conversion of Series C Convertible Preferred Stock and up to 5,685,049 shares issuable upon exercise of warrants, both resulting from a private investment in public equity (PIPE) financing under a Securities Purchase Agreement dated September 30, 2024. Aclarion is not selling any securities under this prospectus and will not receive proceeds from the sale of shares by the Selling Stockholders. However, the company may receive approximately $1.2 million from the cash exercise of the Common Warrants. The shares are to be sold by Selling Stockholders from time to time, at market prices or in negotiated transactions. Aclarion's common stock is listed on the Nasdaq Capital Market under the symbol 'ACON.' The company has received deficiency letters from Nasdaq for not complying with the minimum bid price and stockholders' equity requirements and is subject to potential delisting. Aclarion plans to implement a reverse stock split to regain compliance. The company has appealed the delisting notices and has been granted an extension until January 31, 2025, to demonstrate compliance.
Aclarion公司是一家醫療科技公司,已向SEC提交了招股說明書,詳細說明了最多27,515,153股普通股的發行和轉售。其中包括最多21,830,104股可轉換的C輪可換股優先股所得的股份,以及最多5,685,049股可通過行使認股權而獲得的股份,這兩者均源自2024年9月30日簽訂的證券購買協議下的私募公募股權(PIPE)融資。Aclarion公司不會在本招股說明書項下出售任何證券,並不會從賣方股東出售的股票交易中獲得收入。但是,該公司可能從認股權現金行使中獲得約120萬美元。股份將由賣方股東不時以市場價格或協商交易方式出售。Aclarion的普通股在納斯達克資本市場上以標的爲'ACON'進行交易。公司已收到來自納斯達克的不符合最低買賣價和股東權益要求的違規通知,並可能被除牌。Aclarion計劃實施股票的逆向拆分以恢復合規性。公司已上訴除牌通知,並已獲得延期至2025年1月31日展示合規性的期限。
Aclarion公司是一家醫療科技公司,已向SEC提交了招股說明書,詳細說明了最多27,515,153股普通股的發行和轉售。其中包括最多21,830,104股可轉換的C輪可換股優先股所得的股份,以及最多5,685,049股可通過行使認股權而獲得的股份,這兩者均源自2024年9月30日簽訂的證券購買協議下的私募公募股權(PIPE)融資。Aclarion公司不會在本招股說明書項下出售任何證券,並不會從賣方股東出售的股票交易中獲得收入。但是,該公司可能從認股權現金行使中獲得約120萬美元。股份將由賣方股東不時以市場價格或協商交易方式出售。Aclarion的普通股在納斯達克資本市場上以標的爲'ACON'進行交易。公司已收到來自納斯達克的不符合最低買賣價和股東權益要求的違規通知,並可能被除牌。Aclarion計劃實施股票的逆向拆分以恢復合規性。公司已上訴除牌通知,並已獲得延期至2025年1月31日展示合規性的期限。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息